Cargando…

Ultrastructural Analysis of Cancer Cells Treated with the Radiopharmaceutical Radium Dichloride ([(223)Ra]RaCl(2)): Understanding the Effect on Cell Structure

The use of alpha-particle (α-particle) radionuclides, especially [(223)Ra]RaCl(2) (radium dichloride), for targeted alpha therapy is steadily increasing. Despite the positive clinical outcomes of this therapy, very little data are available about the effect on the ultrastructure of cells. The purpos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diniz Filho, Joel Félix Silva, de Barros, Aline Oliveira da Silva, Pijeira, Martha Sahylí Ortega, Ricci-Junior, Eduardo, Midlej, Victor, Baroni, Mariana Pelissari Monteiro Aguiar, dos Santos, Clenilton Costa, Alencar, Luciana Magalhães Rebelo, Santos-Oliveira, Ralph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913731/ https://www.ncbi.nlm.nih.gov/pubmed/36766793 http://dx.doi.org/10.3390/cells12030451

Ejemplares similares

Nanomicelles of Radium Dichloride [(223)Ra]RaCl(2) Co-Loaded with Radioactive Gold [(198)Au]Au Nanoparticles for Targeted Alpha–Beta Radionuclide Therapy of Osteosarcoma
por: Souza, Bárbara Nayane Rosário Fernandes, et al.
Publicado: (2022)

[(223)Ra] RaCl(2) nanomicelles showed potent effect against osteosarcoma: targeted alpha therapy in the nanotechnology era
por: Yang, Yang, et al.
Publicado: (2022)

Comparing absorbed doses and radiation risk of the α-emitting bone-seekers [(223)Ra]RaCl(2) and [(224)Ra]RaCl(2)
por: Lassmann, Michael, et al.
Publicado: (2023)

Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [(223)Ra]RaCl(2) therapy
por: Sraieb, Miriam, et al.
Publicado: (2020)

Radium 223 dichloride for prostate cancer treatment
por: Deshayes, Emmanuel, et al.
Publicado: (2017)

α-Particle-induced DNA damage tracks in peripheral blood mononuclear cells of [(223)Ra]RaCl(2)-treated prostate cancer patients
por: Schumann, S., et al.
Publicado: (2021)

(223)Ra-dichloride therapy of bone metastasis: optimization of SPECT images for quantification
por: Benabdallah, Nadia, et al.
Publicado: (2019)

Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA
por: Sartor, Oliver, et al.
Publicado: (2016)

Analysis of Unusual Adverse Effects After Radium-223 Dichloride  Administration
por: Frantellizzi, Viviana, et al.
Publicado: (2020)

Response to (223)Ra-dichloride in castration-resistant prostate cancer with bone metastasis: A case report
por: Cabrera, Montserrat Estorch, et al.
Publicado: (2016)

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)

The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study
por: De Feo, Maria Silvia, et al.
Publicado: (2023)

Fine Structures in $^{14}C$ Emission of $^{223}Ra$ and $^{224}Ra$
por: Hourani, E, et al.
Publicado: (1991)

Quantitative measurement of (219)Rn radioactivity in exhaled breath from patients with bone metastasis of castration-resistant prostate cancer treated with (223)RaCl(2)
por: Ooe, Kazuhiro, et al.
Publicado: (2019)

(223)Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice
por: Dizdarevic, Sabina, et al.
Publicado: (2018)

Laser isotope separation of (223)Ra
por: Suryanarayana, M. V.
Publicado: (2023)

Atezolizumab-Conjugated Poly(lactic acid)/Poly(vinyl alcohol) Nanoparticles as Pharmaceutical Part Candidates for Radiopharmaceuticals
por: Ekinci, Meliha, et al.
Publicado: (2022)

Fine structure in 14C emission from 223Ra and 224Ra
por: Hourani, E, et al.
Publicado: (1991)

Scintigraphic Load of Bone Disease Evaluated by DASciS Software as a Survival Predictor in Metastatic Castration-resistant Prostate Cancer Patients Candidates to 223RaCl Treatment
por: Frantellizzi, Viviana, et al.
Publicado: (2019)

Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
por: Gayed, Isis, et al.
Publicado: (2018)

Temperature effects on alpha radioactivity of $^{223}$Ra
por: Huber, Gerhard, et al.
Publicado: (2006)

Ra223 in Bone Metastases with Osteolytic Activity
por: Costa, Renato Patrizio, et al.
Publicado: (2018)

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
por: Nilsson, S., et al.
Publicado: (2016)

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases
por: Ogawa, Kazuma, et al.
Publicado: (2020)

Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model
por: Suominen, Mari I., et al.
Publicado: (2021)

Submarine groundwater discharge data at meter scale ((223)Ra, (224)Ra, (226)Ra, (228)Ra and (222)Rn) in Indian River Bay (Delaware, US)
por: Duque, Carlos, et al.
Publicado: (2019)

Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone
por: Takalkar, Amol, et al.
Publicado: (2014)

Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer
por: Renzulli, Joseph F, et al.
Publicado: (2015)

Safety and Efficacy of (177)Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing (223)Radium-Dichloride
por: Baumgarten, Justus, et al.
Publicado: (2022)

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2021)

Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study
por: Bauckneht, Matteo, et al.
Publicado: (2022)

The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)
por: Bauckneht, Matteo, et al.
Publicado: (2021)

Evolution of Octupole Deformation in Radium Nuclei from Coulomb Excitation of Radioactive $^{222}\mathrm{Ra}$ and $^{228}\mathrm{Ra}$ Beams
por: Butler, P.A., et al.
Publicado: (2020)

A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease
por: Coleman, Robert, et al.
Publicado: (2014)

Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2019)

$^{223}$Ra nuclear spectroscopy in $^{14}$C cluster radioactivity
por: Hourany, E, et al.
Publicado: (1995)

Radiobiological effects of the alpha emitter Ra-223 on tumor cells
por: Bannik, Kristina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oltiq941mio59nnb8v564utopk